Bio-Rad Laboratories BIO Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 51.9%-1.6pp | 51.9%-1.9pp | 52.3%-2.1pp | 52.8%-1.1pp | 53.5%+0.1pp | |
| Net margin | 6.5%+91.7pp | 29.4%+101pp | -26.4%+3.8pp | 12.5%+64.2pp | -85.2%-72.8pp | |
| Returns | ||||||
| Return on equity | 2.5%+30.0pp | 10.8%+34.9pp | -9.5%+0.3pp | 4.6%+22.0pp | -27.5%-24.1pp | |
| Return on invested capital | 11.4%+8.6pp | 10.7%+7.6pp | 2.8%-0.7pp | 2%-1.9pp | 2.8%-0.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.3×0.0× | 0.2×0.0× | |
| Liquidity | ||||||
| Current ratio | 3.2×-2.8× | 5.6×-0.9× | 5.4×-0.7× | 5.1×-1.2× | 6×-0.6× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×-0.1× | 0.2×0.0× | 0.2×0.0× | 0.2×0.0× | 0.2×+0.1× | |
| Per Share | ||||||
| Book value per share | $254.15+6.4% | $273.22+17.3% | $250.22-6.5% | $261.82+9.7% | $238.93-24.7% | |
| Valuation | ||||||
| Market capitalization | $7.52B+10.3% | $8.17B-11.1% | $7.59B-18.6% | $6.47B-16.9% | $6.82B-30.8% | |
| Price / sales | 2.9×+0.2× | 3.2×-0.4× | 3×-0.6× | 2.5×-0.5× | 2.7×-1.1× | |
| Price / book | 1.1×+0.1× | 1.1×-0.3× | 1.1×-0.1× | 0.9×-0.2× | 1×-0.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Bio-Rad Laboratories's profit margins?
- Bio-Rad Laboratories (BIO) runs a 51.9% gross margin and a 8.8% operating margin, with a 6.5% net margin.
- Where do Bio-Rad Laboratories's ratios come from?
- Every ratio is computed from Bio-Rad Laboratories's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
